Zobrazeno 1 - 10
of 23
pro vyhledávání: '"M Tovar Pozo"'
Autor:
A De Lorenzo-Pinto, RM Romero-Jiménez, A Ribed-Sánchez, E Lallana-Sainz, E Chamorro, Ana Herranz-Alonso, Roberto Collado-Borrell, María Sanjurjo-Sáez, M Tovar-Pozo, Alvaro Gimenez-Manzorro
Publikováno v:
European Journal of Hospital Pharmacy. 23:A222.3-A223
Background The new direct acting antiviral (DAA) agents mean a breakthrough in the treatment of hepatitis C virus. However, these DAA agents are not free of drug-drug interactions (DDI), which can significantly reduce their effectiveness or produce a
Autor:
Xandra García-González, CG Rodriguez-Gonzalez, J Leal de la Encina, RM Romero-Jiménez, Ana Herranz-Alonso, M Tovar-Pozo, Vicente Escudero-Vilaplana, María Sanjurjo-Sáez, O Mejias-Gomez, S Osorio-Prendes
Publikováno v:
European Journal of Hospital Pharmacy. 23:A2.2-A3
Background Literature states the importance of medication adherence in the effectiveness of deferasirox for the treatment of transfusional iron overload in some hematologic pathologies such as β thalassemia or sickle-cell disease. However, there is
Autor:
Alvaro Gimenez-Manzorro, Sara Ibáñez-García, AM Gomez-Marquez, María Sanjurjo-Sáez, RM Romero-Jiménez, C Martinez-Fernandez-Llamazares, CG Rodriguez-Gonzalez, Ana Herranz-Alonso, Esther Chamorro-de-Vega, M Tovar-Pozo
Publikováno v:
European Journal of Hospital Pharmacy. 23:A50.2-A51
Background Patients who have recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) have substantial rates of morbidity and mortality. Evaluation of experience with new drug regimens is critical. Purpose The aim was to describe
Autor:
María Sanjurjo-Sáez, Vicente Escudero-Vilaplana, Beatriz Monje, M Tovar-Pozo, JL Revuelta, C Ortega-Navarro, Xandra García-González
Publikováno v:
European Journal of Hospital Pharmacy. 23:A13.3-A14
Background In April 2009, lenalidomide was included in the hospital formulary for the treatment of multiple myeloma (MM) in patients who had received at least one previous therapy. The recommended starting dose (25 mg of lenalidomide) should be adjus
Autor:
Xandra García-González, María Sanjurjo-Sáez, José Luis Revuelta-Herrero, M Tovar-Pozo, Raquel García-Sánchez, R Collado-Borrel, A De Lorenzo-Pinto
Publikováno v:
European Journal of Hospital Pharmacy. 23:A219.3-A220
Background In 2009, the American Food and Drug Administration (FDA) issued an alert that transdermal patches containing metallic components can overheat during MRI or defibrillation procedures and can cause skin burns. In Europe, the information conc
Autor:
María Sanjurjo-Sáez, Vicente Escudero-Vilaplana, MA Ais-Larisgoitia, Ana Herranz-Alonso, M Tovar-Pozo, CG Rodriguez-Gonzalez, A Ribed-Sánchez
Publikováno v:
European Journal of Hospital Pharmacy. 23:A109.2-A110
Background The introduction of robotic dispensing systems in outpatient pharmacies (OP) has increased in recent years. However, there are no data available on its impact on patient safety using a prospective risk analysis. Purpose To evaluate safety
CP-102 Pharmaceutical care monitoring of hepatitis C outpatients: Guaranteeing safety and efficiency
Autor:
GM Alvaro, SG Camino, María Sanjurjo-Sáez, Roberto Collado-Borrell, Ana Herranz-Alonso, M Tovar-Pozo, Sara Ibáñez-García, CG Rodriguez-Gonzalez, LS Elena, Almudena Ribed
Publikováno v:
European Journal of Hospital Pharmacy. 23:A44.3-A45
Background The recent development of highly effective interferon free drug regimens has dramatically changed the therapeutic landscape of hepatitis C virus (HCV). An intensive pharmaceutical care programme is necessary, due to their recent commercial
Autor:
Almudena Ribed, Ana Herranz-Alonso, Alvaro Gimenez-Manzorro, M Tovar-Pozo, E Chamorro de Vega, E Lallana-Sainz, B. Marzal Alfaro, Camino Sarobe-González, María Sanjurjo-Sáez, C Ruiz-Martínez
Publikováno v:
European Journal of Hospital Pharmacy. 23:A141.2-A141
Background The recent development of new drugs has changed radically the treatment of chronic hepatitis C virus (HCV) infection, from interferon (IFN) based treatments to treatments based on direct acting antivirals (DAA). These drugs are thought to
Autor:
B. Marzal Alfaro, Almudena Ribed, Ana Herranz-Alonso, A De Lorenzo-Pinto, JL Revuelta, C Ortega Navarro, M Tovar-Pozo, María Sanjurjo-Sáez, ML Martin-Barbero
Publikováno v:
European Journal of Hospital Pharmacy. 23:A141.1-A141
Background Mobility impairment is a major concern for patients with multiple sclerosis (MS). Dalfampridine improves walking speed. Nevertheless, it entails self-administration and there are few data on adherence rate, patient satisfaction and quality
Autor:
X García González, RM Romero Jiménez, M Tovar Pozo, C Ortega Navarro, C Ruiz Martinez, JL Revuelta, B Monje, M Sanjurjo Sáez, S Pernía
Publikováno v:
European Journal of Hospital Pharmacy. 23:A241.1-A241
Background According to the Institute of Medicine, inadequate medication labelling accounts for 33% of medication errors. As part of the institutional risk management strategy, in 2015 a multidisciplinary team redesigned the labels for hospital compo